All In MedTech

Device Trial Radar · NCT07925580

Trial of Self-Applied Transcutaneous Auricular Vagus Nerve Stimulation for Chemotherapy-Induced Peripheral Neuropathy

Single-Arm Bayesian Phase II Trial of Self-Applied Transcutaneous Auricular Vagus Nerve Stimulation for Chemotherapy-Induced Peripheral Neuropathy

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

55

Planned (sponsor's estimate)

Start

Jan 2027

Primary completion

Jun 30, 2029

Study completion Dec 30, 2029

Sponsor

Lead sponsor
University of MiamiAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Gabrielle's Angel Foundation for Cancer Research
First posted
Nov 9, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This purpose of this study is to evaluate whether transcutaneous auricular vagus nerve stimulation (taVNS) improves chemotherapy-induced peripheral neuropathy (CIPN) symptoms by assessing changes in daily symptom trajectories following treatment initiation. The study will also examine potential mechanisms of action through longitudinal assessment of inflammatory biomarkers, corticospinal excitability, and autonomic nervous system function.

Conditions

  • Chemotherapy Induced Peripheral Neuropathy (CIPN)

Interventions

  • Sparrow Link (taVNS)Device

    Participants will self-administer transcutaneous auricular vagus nerve stimulation (taVNS) using the Sparrow Link portable stimulator and flexible ear electrodes for 1 hour daily for 14 days (total stimulation time: 14 hours).The treatment stimulation intensity can be increased up to 5mA, but this will be adjusted for each participant to ensure it is below the pain threshold.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Daily Chemotherapy-Induced Peripheral Neuropathy Symptom Severity Measured by Numeric Rating Scale (NRS)Time frame: Baseline (Days -14 to 0), Treatment period (Day 1-14)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Christine E Lynn Rehabilitation Center

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.